New compound that locks a disease-related protein into an inactive position stifled the growth of an aggressive form of leukemia.
Scientists have discovered that a common drug given to arthritis sufferers could also help to treat patients with blood cancers.
A recently developed drug holds great promise for some children with acute lymphoblastic leukemia (ALL).
An experimental new treatment approach could buy patients with a rare and dangerous leukemia type the time to obtain a stem cell transplant.
Can molecules derived from avocados be used as a tool to combat leukemia?
Majority of existing drugs for hematologic cancers are priced too high to be considered cost-effective in the United States.
The combination of ibrutinib and chemotherapy (bendamustine and rituximab [BR]) was found to reduce the risk of death by nearly 80% in patients with previously treated CLL or SLL.
Survey compares attitudes and beliefs toward palliative care among hematologic versus solid tumor specialists.
One more potential benefit for breastfed babies, research suggests, is a lowered risk of childhood leukemia.
A new meta-analysis of 26 factors has resulted in an internationally applicable prognostic index for patients with chronic lymphocytic leukemia, according to study results presented at 2015 ASCO Annual Meeting.
[Blood and Lymphatic Cancer: Targets and Therapy] The article discusses the history, use, and evolution of rituximab in the treatment of CLL and examines the next generation CD20 antibodies ofatumumab and obinutuzumab.
Transitioning a long-standing intensive chemotherapy regimen for acute myeloid leukemia (AML) to the outpatient setting is safe and feasible.
Researchers have developed a new drug that shows potential as a treatment for a rare type of acute leukemia, according to a recent study.
A mutation of the gene ETV6 has been pinpointed as the heritable, genetic cause of acute lymphoblastic leukemia (ALL), according to a study.
Researchers have developed a compound that delays leukemia in mice and kills leukemia cells in human tissue samples, which gives hope it could be used to improve regular leukemia therapy.
What data are available concerning inter- and intrapatient variability in the pharmacokinetics of TKIs in chronic myeloid leukemia?
A measurement of the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy may allow for better matching of patients to the optimal intensity of chemotherapy.
Current research indicates that a rare but aggressive subtype of pediatric acute lymphoblastic leukemia (ALL) has surprisingly few mutations beyond the chromosomal rearrangement that affects the MLL gene.
Acute lymphoblastic leukemia (ALL) has been found to have two distinct subtypes, and evidence indicates that roughly 13% of ALL cases may be successfully treated with targeted drugs used in the treatment of lymphomas in adults.
Breastfeeding a child may reduce that child's risk of developing pediatric acute lymphoblastic leukemia (ALL).
Presence of this protein indicates a likely toxicity effect associated with chemotherapy in acute myeloid leukemia (AML).
Children with acute lymphoblastic leukemia with a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study.
A tenth of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase inhibitor ibrutinib because of disease progression during clinical trials, according to a study.
An increase in genetic mutations that could trigger leukemia seems to be a part of aging, according to a new study, but just having cancer-linked DNA doesn't mean the disease will develop.
A previously unrecognized action as a potent inhibitor of the dominant mutation that confers drug resistance to all well-tolerated treatments in patients with certain leukemia types has been found in Axitinib.
Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemiaFebruary 27, 2015
About 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued their therapy due to disease progression during clinical studies.
A subset of antiviral immune cells could prevent CMV infections in bone marrow transplant recipientsFebruary 24, 2015
A small subset of antiviral immune cells may be enough to fight and even prevent the disease caused by cytomegalovirus (CMV) in patients that receive bone marrow transplants.
Young adult survivors of leukemia and lymphoma are more likely to report high stress compared with older survivors of the same diseases.
The ASCO has announced that the transformation of treatment for chronic lymphocytic leukemia (CLL) is its Cancer Advance of the Year.
A new test may reveal which patients will respond to treatment for graft-versus-host disease (GVHD), a serious complication that can arise from stem cell SCT.
- Avocados may hold the answer to beating leukemia
- Cardio-oncology services may improve patient care if more widely available
- Acrylamide in Food and Cancer Risk (Fact Sheet)
- Managing oral oncology/hematology treatments in your practice
- Universal health literacy precautions recommended to assist patient understanding
- Multiple myeloma uses "wolf in sheep's clothing" tactic to avoid immune response in bone
- Comparison of zoledronic acid dosing schedules finds less frequent schedule noninferior
- HPV16 detection after oropharyngeal cancer treatment may increase risk for recurrence
- Delayed referrals, diagnoses undermine cancer patients' faith in health care system
- Alcohol Consumption Linked with Less Disability in Chronic Pain
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|